in4thelonghaul

5 Potential Buyout Targets in Biotech - Barron's

I would add to that list BIIB...considering the absurd sh/pr hit which Biogen has taken on Tysabri and the fact that Carl Icahn is accumulating. ELN is of course caught up in the same recent events and is also a prime target for acquisition by either Wyeth (WYE) or Biogen Idec (BIIB).

Add Dendreon (DNDN) to the list if their interim analysis of Provenge (October estimate) for end-stage prostate cancer is sufficiently positive to allow for immediate trial cessation and refiling of BLA...I would give them roughly a 75% chance of sufficient success at the interim btw.